Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Gary Huang

Otolaryngology Akron, OH Medical Doctor

NPI 1326432634 CMS profile 4220509

55 Arch St Ste 2A, Akron, OH 44304

Open in the dashboard

General payments

$6,461

97 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gary Huang of Akron, OH is reported in the CMS Open Payments database as having received $6,461 across 97 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,432 26
2024 General $903 18
2023 General $2,032 23
2022 General $712 21
2021 General $277 8
2020 General $105 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gary Huang
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Gary Huang were reported at $2,432. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Gary Huang Otolaryngology median Middle half National median
2019 $0 $194 $82–$512 $163
2020 $105 $118 $42–$280 $114
2021 $277 $167 $63–$444 $132
2022 $712 $216 $84–$545 $149
2023 $2,032 $235 $93–$588 $160
2024 $903 $280 $111–$699 $164
2025 $2,432 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Inspire Medical Systems, Inc. $2,075 26 payments
  2. Aerin Medical Inc. $1,785 14 payments
  3. Cochlear Americas $572 12 payments
  4. Stryker Corporation $464 5 payments
  5. Regeneron Healthcare Solutions, Inc. $360 13 payments
  6. Smith+Nephew, Inc. $237 2 payments
  7. Genzyme Corporation $193 4 payments
  8. OptiNose US, Inc. $173 10 payments
  9. Advanced Bionics, LLC $123 1 payment
  10. Medtronic, Inc. $120 3 payments
  11. Other $359 7 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $4,623 84 payments
  2. Travel and Lodging $1,617 10 payments
  3. Education $161 2 payments
  4. Consulting Fee $60 1 payment
Products named General payments · program years 2020–2025
  1. INSPIRE $2,075 26 payments
  2. VIVAER STYLUS $1,785 14 payments
  3. BAHA $559 11 payments
  4. Cochlear Nucleus CI632 cochlear implant with Slim Modiolar electrode $345 7 payments
  5. OSIA OSI300 IMPLANT $333 6 payments
  6. DUPIXENT Inflammation And Immunology $304 12 payments
  7. Cochlear Implantable hearing solution $227 5 payments
  8. Cochlear Implantable hearing solution $227 5 payments
  9. DUPIXENT Immunology $219 5 payments
  10. SCOPIS ENT $214 2 payments
  11. Other $1,643 35 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

289

Median for Otolaryngology: 297

Drug cost

$6,105

Median for Otolaryngology: $6,314

Branded share of claims

0%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Azelastine Hcl Generic 99 $2,775
Fluticasone Propionate Generic 66 $1,012
Ofloxacin Generic 23 $884
Fluocinolone Acetonide Oil Generic 11 $530
Ipratropium Bromide Generic 25 $443
Doxycycline Hyclate Generic 15 $189
Pantoprazole Sodium Generic 23 $160
Cephalexin Generic 11 $72
Tramadol Hcl Generic 16 $41

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$40,011

Medicare's payments for the services billed

Medicare patients

131

Average age 72

Services billed

329

72 women, 59 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 27%
Ischemic heart disease 27%
Chronic kidney disease 27%
Depression 26%
COPD 19%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

97 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record